Illumina, Inc. (ILMN) Receives $175.02 Consensus Target Price from Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN) have received a consensus recommendation of “Hold” from the twenty-four ratings firms that are covering the company, MarketBeat reports. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and ten have issued a buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $175.02.

A number of brokerages recently weighed in on ILMN. Vetr lowered shares of Illumina from a “buy” rating to a “hold” rating and set a $209.78 price target for the company. in a report on Thursday. BidaskClub lowered shares of Illumina from a “hold” rating to a “sell” rating in a report on Thursday, August 17th. Barclays PLC reissued an “equal weight” rating and issued a $150.00 price target on shares of Illumina in a report on Wednesday, August 9th. Canaccord Genuity raised shares of Illumina from a “hold” rating to a “buy” rating and raised their price target for the company from $170.00 to $215.00 in a report on Monday, August 7th. Finally, Zacks Investment Research lowered shares of Illumina from a “buy” rating to a “hold” rating in a report on Friday, August 4th.

In related news, Director Jay T. Flatley sold 20,000 shares of the business’s stock in a transaction on Tuesday, June 6th. The shares were sold at an average price of $180.24, for a total value of $3,604,800.00. Following the sale, the director now directly owns 539,176 shares of the company’s stock, valued at approximately $97,181,082.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Charles Dadswell sold 145 shares of the business’s stock in a transaction on Monday, June 5th. The shares were sold at an average price of $184.75, for a total transaction of $26,788.75. Following the completion of the sale, the senior vice president now directly owns 10,791 shares in the company, valued at $1,993,637.25. The disclosure for this sale can be found here. Insiders sold a total of 165,951 shares of company stock valued at $30,578,030 in the last three months. 1.60% of the stock is owned by company insiders.

A number of large investors have recently bought and sold shares of the stock. Advisory Services Network LLC acquired a new stake in shares of Illumina during the first quarter valued at approximately $117,000. Penserra Capital Management LLC boosted its stake in shares of Illumina by 13.0% in the second quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock valued at $153,000 after buying an additional 102 shares during the period. Paradigm Asset Management Co. LLC boosted its stake in shares of Illumina by 5.6% in the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock valued at $165,000 after buying an additional 50 shares during the period. Patten Group Inc. boosted its stake in shares of Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after buying an additional 25 shares during the period. Finally, NN Investment Partners Holdings N.V. boosted its stake in shares of Illumina by 11.3% in the second quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock valued at $171,000 after buying an additional 100 shares during the period. 93.32% of the stock is currently owned by institutional investors and hedge funds.

Shares of Illumina (NASDAQ ILMN) traded up 1.32% during mid-day trading on Wednesday, hitting $207.15. The stock had a trading volume of 824,566 shares. The firm has a 50 day moving average of $187.91 and a 200 day moving average of $177.34. The stock has a market cap of $30.24 billion, a price-to-earnings ratio of 41.56 and a beta of 0.80. Illumina has a one year low of $119.37 and a one year high of $207.49.

Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The company had revenue of $662 million during the quarter, compared to analysts’ expectations of $642.38 million. During the same quarter in the previous year, the company posted $0.86 earnings per share. Illumina’s quarterly revenue was up 10.3% compared to the same quarter last year. On average, analysts forecast that Illumina will post $3.65 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Illumina, Inc. (ILMN) Receives $175.02 Consensus Target Price from Analysts” was reported by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.truebluetribune.com/2017/09/17/illumina-inc-ilmn-receives-175-02-consensus-target-price-from-analysts.html.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply